Altevax' pioneering immunotherapy relies on a melanin-based vaccine adjuvant, which has been proven in pre-clinical trials. This technology triggers an immune response with CD8+ T cells, the body’s most powerful defenders, that is specific to an embedded antigen. This immune response is stronger, faster and more effective than alternative technologies. Altevax' core development is for a glioblastoma therapeutic vaccine.